An opportunity for longer survival
People who received ERBITUX with FOLFIRI who had KRAS wild-type, EGFR-expressing tumors were shown to live 4 months longer compared to people treated with FOLFIRI alone (23.5 months compared to 19.5 months, respectively).
Median overall survival
SELECT SAFETY INFORMATION
ERBITUX can cause lung disease. Lung disease occurred in less than 0.5% of 1570 patients receiving ERBITUX in clinical trials for colorectal cancer and head and neck cancer; 1 patient died.
- Notify your doctor if you develop shortness of breath, a new or worsening cough and/or chest pain while receiving ERBITUX
- ERBITUX treatment should be stopped if breathing symptoms worsen, and should not be restarted if lung disease is diagnosed
A chance to slow the progression of your tumor
In the subgroup of people with KRAS wild-type, EGFR-expressing tumors, the length of time some people lived without their cancer growing or spreading was longer for those receiving ERBITUX with FOLFIRI (9.5 months) than FOLFIRI alone (8.1 months).
Median progression-free survival
Shown to shrink tumors in some people
In this subgroup, ERBITUX with FOLFIRI was also shown to shrink tumors in some people. 57% of 320 people saw a reduction in combined tumor size (reduction of 50% or more) compared to 39% of 356 people treated with FOLFIRI alone.†
Overall response rate
The safety and effectiveness for ERBITUX are different for everyone. Individual results may vary. Your doctor is the best person to talk to about ERBITUX, what it may offer, and whether it’s the right option for you.